Cargando…

Impact of COVID-19 on cancer screening in South Korea

The coronavirus disease (COVID-19) pandemic significantly declined cancer screening rates worldwide. Its impact on the South Korean population is unclear, depending on socioeconomic status (SES), residence, and history of chronic disease. This study utilized data (2018–2020) from the Korean National...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyeonmin, Lee, Yun Yeong, Suh, Mina, Jun, Jae Kwan, Park, Bomi, Kim, Yeol, Choi, Kui Son
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255521/
https://www.ncbi.nlm.nih.gov/pubmed/35790880
http://dx.doi.org/10.1038/s41598-022-15778-3
_version_ 1784740938129604608
author Lee, Kyeonmin
Lee, Yun Yeong
Suh, Mina
Jun, Jae Kwan
Park, Bomi
Kim, Yeol
Choi, Kui Son
author_facet Lee, Kyeonmin
Lee, Yun Yeong
Suh, Mina
Jun, Jae Kwan
Park, Bomi
Kim, Yeol
Choi, Kui Son
author_sort Lee, Kyeonmin
collection PubMed
description The coronavirus disease (COVID-19) pandemic significantly declined cancer screening rates worldwide. Its impact on the South Korean population is unclear, depending on socioeconomic status (SES), residence, and history of chronic disease. This study utilized data (2018–2020) from the Korean National Cancer Screening Survey, an annual cross-sectional study employing nationally representative random sampling. Cancer screening rates were defined as the proportion of the eligible population who received respective cancer screening within the last 1 year and investigated four major cancers (stomach, colorectal, breast, and cervical). Screening rates every year were compared with screening rate ratios (SRRs) and the corresponding 95% confidence intervals (CIs). Between 2019 and 2020, screening rates declined significantly by 23%, 17%, 12%, and 8% for colorectal cancer (SRR 0.77; 95% CI 0.73–0.82), stomach cancer (SRR 0.83; 95% CI 0.79–0.87), breast cancer (SRR 0.88; 95% CI 0.82–0.93), and cervical cancer (SRR 0.92; 95% CI 0.87–0.97), respectively. Regardless of cancer type, screening was significantly lower in metropolitan residents, those with higher SES, and, interestingly, those without a history of chronic diseases. The significant decline in cancer screening during the pandemic requires urgent political intervention to reduce the burden of future cancer incidence and mortality.
format Online
Article
Text
id pubmed-9255521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92555212022-07-06 Impact of COVID-19 on cancer screening in South Korea Lee, Kyeonmin Lee, Yun Yeong Suh, Mina Jun, Jae Kwan Park, Bomi Kim, Yeol Choi, Kui Son Sci Rep Article The coronavirus disease (COVID-19) pandemic significantly declined cancer screening rates worldwide. Its impact on the South Korean population is unclear, depending on socioeconomic status (SES), residence, and history of chronic disease. This study utilized data (2018–2020) from the Korean National Cancer Screening Survey, an annual cross-sectional study employing nationally representative random sampling. Cancer screening rates were defined as the proportion of the eligible population who received respective cancer screening within the last 1 year and investigated four major cancers (stomach, colorectal, breast, and cervical). Screening rates every year were compared with screening rate ratios (SRRs) and the corresponding 95% confidence intervals (CIs). Between 2019 and 2020, screening rates declined significantly by 23%, 17%, 12%, and 8% for colorectal cancer (SRR 0.77; 95% CI 0.73–0.82), stomach cancer (SRR 0.83; 95% CI 0.79–0.87), breast cancer (SRR 0.88; 95% CI 0.82–0.93), and cervical cancer (SRR 0.92; 95% CI 0.87–0.97), respectively. Regardless of cancer type, screening was significantly lower in metropolitan residents, those with higher SES, and, interestingly, those without a history of chronic diseases. The significant decline in cancer screening during the pandemic requires urgent political intervention to reduce the burden of future cancer incidence and mortality. Nature Publishing Group UK 2022-07-05 /pmc/articles/PMC9255521/ /pubmed/35790880 http://dx.doi.org/10.1038/s41598-022-15778-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lee, Kyeonmin
Lee, Yun Yeong
Suh, Mina
Jun, Jae Kwan
Park, Bomi
Kim, Yeol
Choi, Kui Son
Impact of COVID-19 on cancer screening in South Korea
title Impact of COVID-19 on cancer screening in South Korea
title_full Impact of COVID-19 on cancer screening in South Korea
title_fullStr Impact of COVID-19 on cancer screening in South Korea
title_full_unstemmed Impact of COVID-19 on cancer screening in South Korea
title_short Impact of COVID-19 on cancer screening in South Korea
title_sort impact of covid-19 on cancer screening in south korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255521/
https://www.ncbi.nlm.nih.gov/pubmed/35790880
http://dx.doi.org/10.1038/s41598-022-15778-3
work_keys_str_mv AT leekyeonmin impactofcovid19oncancerscreeninginsouthkorea
AT leeyunyeong impactofcovid19oncancerscreeninginsouthkorea
AT suhmina impactofcovid19oncancerscreeninginsouthkorea
AT junjaekwan impactofcovid19oncancerscreeninginsouthkorea
AT parkbomi impactofcovid19oncancerscreeninginsouthkorea
AT kimyeol impactofcovid19oncancerscreeninginsouthkorea
AT choikuison impactofcovid19oncancerscreeninginsouthkorea